Scholar Rock SRRK Business Segments — Net Income Loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Scholar Rock in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Scholar Rock's business segments — net income loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Scholar Rock's business segments — net income loss?
- Scholar Rock (SRRK) reported business segments — net income loss of -$105.51M in Q1 2026.
- How has Scholar Rock's business segments — net income loss changed year-over-year?
- Scholar Rock's business segments — net income loss decreased by 41.2% year-over-year, from -$74.72M to -$105.51M.
- What is the long-term trend for Scholar Rock's business segments — net income loss?
- Over 2 years (2023 to 2025), Scholar Rock's business segments — net income loss has grown at a 51.0% compound annual growth rate (CAGR), from -$165.79M to -$377.94M.
- What does business segments — net income loss mean?
- This represents the bottom-line financial result for the business segment after accounting for all revenues, operating expenses, and non-operating items. It is the primary indicator of the segment's overall financial health and sustainability. For early-stage biopharmaceutical companies, this metric typically highlights the ongoing cash burn required to fund clinical development.